You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 28, 2024

CRIXIVAN Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


When do Crixivan patents expire, and what generic alternatives are available?

Crixivan is a drug marketed by Merck Sharp Dohme and is included in one NDA.

The generic ingredient in CRIXIVAN is indinavir sulfate. There are two drug master file entries for this compound. Additional details are available on the indinavir sulfate profile page.

Summary for CRIXIVAN
Drug patent expirations by year for CRIXIVAN
Drug Prices for CRIXIVAN

See drug prices for CRIXIVAN

Recent Clinical Trials for CRIXIVAN

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Oncology Institute of Southern SwitzerlandPhase 2
Emory UniversityPhase 4
National Institutes of Health Clinical Center (CC)Phase 1

See all CRIXIVAN clinical trials

US Patents and Regulatory Information for CRIXIVAN

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Merck Sharp Dohme CRIXIVAN indinavir sulfate CAPSULE;ORAL 020685-006 Apr 19, 2000 DISCN No No ⤷  Try a Trial ⤷  Try a Trial ⤷  Try a Trial
Merck Sharp Dohme CRIXIVAN indinavir sulfate CAPSULE;ORAL 020685-001 Mar 13, 1996 DISCN Yes No ⤷  Try a Trial ⤷  Try a Trial ⤷  Try a Trial
Merck Sharp Dohme CRIXIVAN indinavir sulfate CAPSULE;ORAL 020685-003 Mar 13, 1996 DISCN Yes No ⤷  Try a Trial ⤷  Try a Trial ⤷  Try a Trial
Merck Sharp Dohme CRIXIVAN indinavir sulfate CAPSULE;ORAL 020685-005 Dec 17, 1998 DISCN No No ⤷  Try a Trial ⤷  Try a Trial ⤷  Try a Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for CRIXIVAN

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Merck Sharp Dohme CRIXIVAN indinavir sulfate CAPSULE;ORAL 020685-001 Mar 13, 1996 ⤷  Try a Trial ⤷  Try a Trial
Merck Sharp Dohme CRIXIVAN indinavir sulfate CAPSULE;ORAL 020685-006 Apr 19, 2000 ⤷  Try a Trial ⤷  Try a Trial
Merck Sharp Dohme CRIXIVAN indinavir sulfate CAPSULE;ORAL 020685-001 Mar 13, 1996 ⤷  Try a Trial ⤷  Try a Trial
Merck Sharp Dohme CRIXIVAN indinavir sulfate CAPSULE;ORAL 020685-003 Mar 13, 1996 ⤷  Try a Trial ⤷  Try a Trial
Merck Sharp Dohme CRIXIVAN indinavir sulfate CAPSULE;ORAL 020685-005 Dec 17, 1998 ⤷  Try a Trial ⤷  Try a Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

International Patents for CRIXIVAN

See the table below for patents covering CRIXIVAN around the world.

Country Patent Number Title Estimated Expiration
Romania 118000 METODA PENTRU TRATAMENTUL SIDA, PREVENIREA SI TRATAMENTUL INFECTIEI CU HIV SAU INHIBAREA PROTEAZEI HIV SI COMPOZITIE FARMACEUTICA PENTRU APLICAREA METODEI (METHOD FOR TREATING AIDS, FOR PREVENTING AND TREATING HIV INFECTION OR INHIBITING HIV PROTEASE AND PHARMACEUTICAL COMPOSITION FOR APPLYING SAID METHOD) ⤷  Try a Trial
Czech Republic 9401110 ⤷  Try a Trial
Norway 941696 ⤷  Try a Trial
Cyprus 2090 Hiv protease inhibitors useful for the treatment of aids ⤷  Try a Trial
Romania 115726 DERIVATI SUBSTITUITI AI PENTANAMIDEI, PROCEDEU DE OBTINERE, INTERMEDIARI IN SINTEZA ACESTORA, COMPOZITIE CARE II CONTINE, SI METODE DE TRATAMENT (SUBSTITUTED DERIVATIVES OF PENTANEAMIDE, PROCESS FOR THEIR PREPARATION, INTERMEDIATES USED IN THEIR SYNTHESIS, COMPOSITION CONTAINING THE SAME AND METHODS OF TREATMENT) ⤷  Try a Trial
>Country >Patent Number >Title >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.